NCT00750698

A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib

A Phase 2, Exploratory Study of Erlotinib and SNDX-275 in Patients With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Syndax Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the tumor responses to SNDX-275 (entinostat) in combination with continued erlotinib in participants with non-small Cell Lung Carcinoma (NSCLC) who are progressing on erlotinib.

Conditions

• Non Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Entinostat	Entinostat (10 milligrams \[mg\] fixed dose orally \[PO\] every 2 weeks \[Q2W\]) on Days 1 and 15 of a 28-day cycle for up to 6 cycles
DRUG	Erlotinib	Erlotinib (150 mg PO QD) for up to six (6) 28-day cycles

Timeline

• Start date: 2008-08-01
• Primary completion: 2010-05-01
• Completion: 2010-06-01
• First posted: 2008-09-10
• Last updated: 2023-07-06
• Results posted: 2023-07-06

Locations

5 sites across 1 country: United States